Merck (MRK) announced that the company has entered into an agreement to receive funds managed by Blackstone Life Sciences (BX) for the development ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has entered into an agreement to receive funds managed by Blackstone Life Sciences ...

Based on strong preclinical data on HMPL-A251 in HER2-positive tumor cell lines, the firm wants to take the therapy into clinical trials by year end.

The latest update is out from Oncopeptides AB ( (SE:ONCO) ).

Based on its Q3 performance, the firm raised its full-year sales and EPS guidance and is now expecting sales to be between ...

Advancing AT-01, a first-in-class ADC programme, with strong preclinical validation towards IND/CTA-enabling studies, expected to begin in the first half of 2026 Leadership and Board strengthened with ...

Zocilurtatug pelitecan (zoci), also known as ZL-1310, an investigational antibody-drug conjugate (ADC) that targets the ...

GameSpot may get a commission from retail offers. This month, Netflix debuted the new animated series, Splinter Cell: Deathwatch, which brings back Tom Clancy's Sam Fisher, the lead character of ...

Splinter Cell: Deathwatch is streaming now on Netflix. For people who decide to give Splinter Cell: Deathwatch a try on Netflix that are unfamiliar with Sam Fisher’s long and incredible run in the ...

Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the ...

Graham Kates is an investigative reporter covering criminal justice, privacy issues and information security for CBS News Digital. Contact Graham at [email protected] or [email protected] ...

Takeda is tapping out of the cell therapy arena as part of a "strategic portfolio reprioritization," with 137 roles at the drugmaker's Massachusetts R&D site affected. The company is seeking a partner ...